Generative AI and drug discovery - what IP considerations are there?
While genAI is revolutionising various fields, its impact on healthcare and chemistry is massive. Its ability to analyse vast amounts of data and generate predictive models has significantly accelerated drug discovery. Laura reviews genAI applications and dives into the associated intellectual property (IP) issues in her latest article.
Stephane Antoine explores the implications of the G1/24 case and highlights the EPO's referral mechanisms for addressing legal interpretations and resolving inconsistencies within patent law.
Attending the world's leading IP events, the Murgitroyd team are always keen to meet with new and existing contacts. Find out what events we'll be attending by clicking the link below.
%20(260%20x%20195%20px).png?upscale=true&width=520&upscale=true&name=In-houseLegal%20Newsletter%20Imagery%20(260%20x%20140%20px)%20(260%20x%20195%20px).png)
